SLITRK4 Inhibitors
Inhibition of SLITRK4's function is achieved through a variety of mechanisms targeting the signaling pathways and cellular processes with which it is associated. Compounds that hinder dopamine signaling, for example, interfere with dopaminergic pathways that regulate neurite outgrowth, a process wherein SLITRK4 has a key role. Similarly, the activity of SLITRK4 is indirectly diminished by chemicals that inhibit GSK-3, a kinase involved in neuronal growth and synaptic stability. These inhibitors modify downstream effects on neuronal differentiation, which is crucial given SLITRK4's implication in these areas. In addition, the inhibition of mitogen-activated protein kinase kinase (MEK) and phosphoinositide 3-kinases (PI3K) disrupts critical pathways such as MAPK/ERK and PI3K/Akt, respectively. These pathways are essential for neuronal differentiation and synaptic plasticity, processes that SLITRK4 could be involved in. As a result, obstructing these pathways can result in reduced SLITRK4 activity related to neurite outgrowth and synaptic connectivity.
Further suppression of SLITRK4's activity is achieved by compounds that target cytoskeletal organization and protein trafficking within neurons. Inhibitors of Rho-associated kinase (ROCK) and Rac1, key regulators of cytoskeletal dynamics, can lead to an indirect reduction in SLITRK4 activity by affecting neurite outgrowth, a process in which SLITRK4 is a known player. Disruption of the Golgi apparatus and subsequent protein transport by specific inhibitors may also lead to a decrease in SLITRK4's functional activity by limiting its cell surface expression. In addition, inhibition of N-WASP-mediated actin polymerization affects the dynamics crucial for neurite extension where SLITRK4 is involved. Lastly, the action of casein kinase 1 (CK1) in cytoskeletal organization and signaling pathways is disrupted by certain inhibitors, potentially leading to a decrease in SLITRK4's functional activity due to altered cytoskeletal organization and signaling events that are critical for SLITRK4's role in neuronal development.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
As a dopamine antagonist, haloperidol specifically binds to dopamine D2 receptors, which are implicated in the regulation of neurite outgrowth. Since SLITRK4 is involved in neurite outgrowth, the dampening of dopaminergic signaling by haloperidol may lead to reduced functional activity of SLITRK4 by decreasing the cellular context for its action in neurite modulation. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits glycogen synthase kinase-3 (GSK-3), a kinase involved in neuronal growth and development. Inhibition of GSK-3 has downstream effects on neuronal differentiation and synaptic stability, which are processes that SLITRK4 could be implicated in. Thus, lithium chloride indirectly decreases SLITRK4 functional activity by modulating these pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
This compound is a specific inhibitor of mitogen-activated protein kinase kinase (MEK), which acts upstream in the MAPK/ERK pathway, a pathway essential for neuronal differentiation and synaptic plasticity. Inhibition of MEK results in reduced ERK pathway signaling, potentially diminishing the functional activity of SLITRK4, which is involved in similar neuronal processes. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of Rho-associated protein kinase (ROCK), which plays a crucial role in cytoskeletal organization affecting neurite outgrowth. Since SLITRK4 is associated with neurite development, inhibition of ROCK by Y-27632 may indirectly lead to decreased functional activity of SLITRK4 in neurite outgrowth and maintenance. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
As an inhibitor of phosphoinositide 3-kinases (PI3K), LY 294002 disrupts the PI3K/Akt signaling pathway, which is involved in neuronal survival and growth. Given that SLITRK4 plays a role in neurite outgrowth, the inhibition of this pathway could lead to a reduction in SLITRK4 functional activity as part of the broader impact on neuronal development. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
This compound inhibits MEK1/2, leading to suppression of the ERK1/2 branch of the MAPK pathway. The MAPK pathway influences neuronal differentiation and synaptic plasticity, processes that could involve SLITRK4. Therefore, inhibition of this pathway by U0126 may indirectly decrease the functional activity of SLITRK4 in these processes. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the Golgi apparatus and inhibits protein transport, which can affect the membrane trafficking of various proteins, including potentially SLITRK4. By disrupting normal protein trafficking, brefeldin A may indirectly decrease the functional activity of SLITRK4 by reducing its presence at the cell surface where it normally functions. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $49.00 $124.00 $441.00 $828.00 | 4 | |
Wiskostatin is a selective inhibitor of N-WASP, a regulator of actin polymerization. Given that SLITRK4 is involved in neurite outgrowth, inhibition of actin polymerization dynamics via N-WASP inhibition could indirectly decrease the functional activity of SLITRK4 in neurite extension and maintenance. | ||||||
Casein Kinase I Inhibitor, D4476 | 301836-43-1 | sc-202522 | 1 mg | $99.00 | 6 | |
D4476 is an inhibitor of casein kinase 1 (CK1), which is involved in multiple cellular processes including Wnt signaling and cytoskeleton dynamics. Inhibition of CK1 by D4476 could indirectly decrease the functional activity of SLITRK4 by affecting the cytoskeletal organization and signaling | ||||||